Compare Flux Power Holdings Inc (FLUX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Flux Power Holdings Inc trades at $0.46 (market cap $9.97M), while Recursion Pharmaceuticals Inc trades at $4.25 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 214.6× Flux Power Holdings Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| FLUX | RXRX | |
|---|---|---|
Market Cap | $9.97M | $2.14B |
Volume | 817,320 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $6.66 | $6.79 |
52-Week Low | $0.41 | $2.84 |
Typical Hold Time | 20 Days | 23 Days |
Enterprise Value | $18.18M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.49, down 0.55% today, amid ongoing acquisition interest from Solidion Technology. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $66M in 2025 to $42M in 2026 and persistent net losses. Despite unanimous analyst buy ratings, recent earnings misses and negative profitability metrics (-17.68% net margin) highlight operational challenges.
The outlook remains speculative with acquisition potential offering upside, but fundamental weakness and cash flow concerns pose significant risks. Investors face a binary outcome between takeover premium and continued operational losses in the competitive energy storage sector.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
